BACKGROUND & AIMS: Late diagnosis of colorectal carcinoma results in a significant reduction of average survival times. Yet despite screening programs, about 70% of tumors are detected at advanced stages (International Union Against Cancer stages III/IV). We explored whether detection of malignant disease would be possible through identification of tumor-specific protein biomarkers in serum samples. METHODS: A discovery set of sera from patients with colorectal malignancy (n = 58) and healthy control individuals (n = 32) were screened for potential differences using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Candidate proteins were identified and their expression levels were validated in independent sample sets using a specific immunoassay (enzyme-linked immunosorbent assay). RESULTS: By using class comparison and custom-developed algorithms we identified several m/z values that were expressed differentially between the malignant samples and the healthy controls of the discovery set. Characterization of the most prominent m/z values revealed a member of the complement system, the stable form of C3a anaphylatoxin (ie, C3a-desArg). Based on a specific enzyme-linked immunosorbent assay, serum levels of complement C3a-desArg predicted the presence of colorectal malignancy in a blinded validation set (n = 59) with a sensitivity of 96.8% and a specificity of 96.2%. Increased serum levels were also detected in 86.1% of independently collected sera from patients with colorectal adenomas (n = 36), whereas only 5.6% were classified as normal. CONCLUSIONS: Complement C3a-desArg is present at significantly higher levels in serum from patients with colorectal adenomas (P < .0001) and carcinomas (P < .0001) than in healthy individuals. This suggests that quantification of C3a-desArg levels could ameliorate existing screening tests for colorectal cancer.
BACKGROUND & AIMS: Late diagnosis of colorectal carcinoma results in a significant reduction of average survival times. Yet despite screening programs, about 70% of tumors are detected at advanced stages (International Union Against Cancer stages III/IV). We explored whether detection of malignant disease would be possible through identification of tumor-specific protein biomarkers in serum samples. METHODS: A discovery set of sera from patients with colorectal malignancy (n = 58) and healthy control individuals (n = 32) were screened for potential differences using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Candidate proteins were identified and their expression levels were validated in independent sample sets using a specific immunoassay (enzyme-linked immunosorbent assay). RESULTS: By using class comparison and custom-developed algorithms we identified several m/z values that were expressed differentially between the malignant samples and the healthy controls of the discovery set. Characterization of the most prominent m/z values revealed a member of the complement system, the stable form of C3a anaphylatoxin (ie, C3a-desArg). Based on a specific enzyme-linked immunosorbent assay, serum levels of complement C3a-desArg predicted the presence of colorectal malignancy in a blinded validation set (n = 59) with a sensitivity of 96.8% and a specificity of 96.2%. Increased serum levels were also detected in 86.1% of independently collected sera from patients with colorectal adenomas (n = 36), whereas only 5.6% were classified as normal. CONCLUSIONS: Complement C3a-desArg is present at significantly higher levels in serum from patients with colorectal adenomas (P < .0001) and carcinomas (P < .0001) than in healthy individuals. This suggests that quantification of C3a-desArg levels could ameliorate existing screening tests for colorectal cancer.
Authors: Emanuel F Petricoin; Kathryn C Zoon; Elise C Kohn; J Carl Barrett; Lance A Liotta Journal: Nat Rev Drug Discov Date: 2002-09 Impact factor: 84.694
Authors: Emanuel F Petricoin; David K Ornstein; Cloud P Paweletz; Ali Ardekani; Paul S Hackett; Ben A Hitt; Alfredo Velassco; Christian Trucco; Laura Wiegand; Kamillah Wood; Charles B Simone; Peter J Levine; W Marston Linehan; Michael R Emmert-Buck; Seth M Steinberg; Elise C Kohn; Lance A Liotta Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta Journal: Lancet Date: 2002-02-16 Impact factor: 79.321
Authors: Bao-Ling Adam; Yinsheng Qu; John W Davis; Michael D Ward; Mary Ann Clements; Lisa H Cazares; O John Semmes; Paul F Schellhammer; Yutaka Yasui; Ziding Feng; George L Wright Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris Journal: Nat Rev Immunol Date: 2017-09-18 Impact factor: 53.106
Authors: E R C G N Galvão; L M S Martins; J O Ibiapina; H M Andrade; S J H Monte Journal: J Cancer Res Clin Oncol Date: 2011-04-05 Impact factor: 4.553
Authors: A Michlmayr; T Bachleitner-Hofmann; S Baumann; M Marchetti-Deschmann; I Rech-Weichselbraun; C Burghuber; U Pluschnig; R Bartsch; A Graf; R Greil; G Allmaier; G Steger; M Gnant; M Bergmann; R Oehler Journal: Br J Cancer Date: 2010-09-28 Impact factor: 7.640